12:00 AM
Mar 26, 2012
 |  BC Week In Review  |  Company News  |  Deals

Heptares, Shire deal

Shire exercised a 2011 option to license exclusive, worldwide rights from Heptares to a preclinical adenosine A2A...

Read the full 75 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >